digital_leader_award_2020
Successful IT transformation recognized: Boehringer Ingelheim wins Digital Leader Award 2020Award values strategic contribution of the IT organization to the innovative strength of the pharmaceutical companyTransformation drives company-wide digital innovationEarly investments in digital technologies have been crucial to maintain business operations under COVID-19     (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2020 Category: Research Source Type: news

Phase II results cognitive impairment schizophrenia
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophreniaResults presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has met its primary endpoint1,2Trial results, together with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, add to the body of evidence for Boehringer Ingelheim ’s schizophrenia research program3Cognitive impairment associated with schizophrenia (CIAS) has a significant negative impact on daily functioning and remains a focus for Boehringer Ingel...
Source: Boehringer Ingelheim Corporate News - September 14, 2020 Category: Research Source Type: news

Partnership-with-clicktherapeutics
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia This collaboration combines Click Therapeutics ’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in clinical development of treatments for neuropsychiatric diseases, furthering Boehringer Ingelheim’s commitment to exploring digital innovations to benefit patients with unmet medica l needsTogether the companies will develop and commercialize a prescription-based digital the...
Source: Boehringer Ingelheim Corporate News - September 11, 2020 Category: Research Source Type: news

Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal CancersFirst-in-class bi-specific antibody BI 905711 activates a pathway in TRAILR2 and CDH17 co-expressing tumor cells that leads to their destructionMay result in a more tolerable and selective therapy for patients affected with gastrointestinal cancers by avoiding liver toxicity commonly observed in other therapy approaches targeting TRAILR2Adds a promising candidate to Boehringer Ingelheim ’s multipronged oncology portfolio that combines cancer cell-directed and cancer immunology ...
Source: Boehringer Ingelheim Corporate News - September 10, 2020 Category: Research Source Type: news

discontinuation-bi-1467335-diabetic-retinopathy
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic RetinopathyBI 1467335 was acquired from Pharmaxis in 2015 as part of Boehringer Ingelheim ’s growing Retinal Health R&D pipeline portfolioBoehringer Ingelheim has terminated the agreement with Pharmaxis with 90 days ’ notice during which time Pharmaxis can request return of all existing data and intellectual property.Boehringer Ingelheim will continue to advance its comprehensive portfolio of next generation retinal therapy approachesPharmaxis will continue its development of small molecule amine oxidase inhibitors with a phase 2 study in myelofib...
Source: Boehringer Ingelheim Corporate News - September 7, 2020 Category: Research Source Type: news

GioTag Final Data
Conclusions from the observational GioTag study were   published in Future OncologyiGiotrif/Gilotrif (afatinib) followed by osimertinib showed median overall survival (OS) of 37.6 months in patients with EGFR mutation-positive NSCLC (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 2, 2020 Category: Research Source Type: news

Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 27, 2020 Category: Research Source Type: news

Launch-of-CARE-Consortium
Europe ’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus ThreatsCARE (Corona Accelerated R&D in Europe), supported by Europe ’s Innovative Medicines Initiative (IMI), is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19The initiative is committed to a long-term understanding of the disease and development of therapies for COVID-19 and future coronavirus threats in addition to urgent efforts to repurpose existing therapies as potential immediate response.The CARE consortium will accelerate COVID-19...
Source: Boehringer Ingelheim Corporate News - August 18, 2020 Category: Research Source Type: news

biolabs-heidelberg
Boehringer Ingelheim Supports BioLabs First European Location BioLabs Heidelberg with Founding Sponsorship   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 17, 2020 Category: Research Source Type: news

InPedILD_trial_enrollment
Phase III InPedILD ™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung diseaseFirst-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globallyThis new study builds on the Phase III INBUILD ® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype1,2,3Global Phase III multicentre clinical trial is planned to be conducted in approximately 70 sites in 24 countries (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 12, 2020 Category: Research Source Type: news

Fight against COVID-19 pandemic shapes global business activities
First half 2020: Fight against COVID-19 pandemic shapes global business activities of Boehringer IngelheimCompany engaged in various initiatives to contain and cope with the global spread of COVID-19Protection of employees and safeguarding of worldwide pharmaceutical supply prioritiesNet sales growth under difficult market conditions – company expects market volatility to remain intense (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 3, 2020 Category: Research Source Type: news

emperor-reduced-heart-failure-toplineresults
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetesEmpagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction  Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2020 Category: Research Source Type: news

Boehringer Ingelheim acquires Global Stem cell Technology
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal HealthBoehringer Ingelheim joins forces with Belgian biotech company GST which develops and produces state-of-the art stem cell products for horses and petsThe acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European marketDecision to acquire GST is fully aligned with part of Boehringer Ingelheim ’s Animal Health strategy, aiming to strengthen its portfolio capabilities to accelerate innovation and growth (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 27, 2020 Category: Research Source Type: news

EC_approval_nintedanib_ILD_PF
European Commission approves third nintedanib indication in pulmonary fibrosis1The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1The decision is based on the results of the INBUILD ® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.2Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstit...
Source: Boehringer Ingelheim Corporate News - July 15, 2020 Category: Research Source Type: news

Perceived burden of COPD is higher for younger patients
Perceived burden of disease is greater in younger people living with COPD, global survey revealsCOPD impacts younger patients ’ daily activities more significantlyYounger patients feel more negative about their diseaseYounger patients want and need more support from HCPs to achieve optimal treatment management    (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2020 Category: Research Source Type: news